Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 12, 2026
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
View original at finance.yahoo.comFinal MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1 Median time-to-next-treatment(TTNT), the study's prima…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Final MINT analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes with mogamulizumab in routine clinical practice.
60% confidenceMINT represents one of the largest real-world evaluations of mogamulizumab in Germany.
60% confidenceExploratory analyses show meaningful responses in subgroups including large cell transformation, folliculotropic MF and MAR status, supporting individualised treatment.
60% confidence
Cited in these Via News reports
- Cancer-drug approvals are stacking up in Q4 2026, but the AI promises and Summit's cash needs are what to check →
- Oncology's Busy Autumn: A Cash-Burning Drugmaker Awaits Its Verdict While AI Promises Faster Medicines →
- Oncology's Next Wave Meets Its Test: Summit's Nov. 14 Ivonescimab Decision, a Record Loss, and AI Claims That Are Still Forecasts →